PRL-3: unveiling a new horizon in cancer therapy
文献类型：期刊论文
| 作者 | Cao, Zi-tong2,5,6; Mao, Jia-luo5,6,7; Huang, Chang-ying1,3,5; Wang, Han-lin1,5; Wang, Ming-zhi6,7; Wang, Wen-long4; Zhou, Yu-bo5,6,7 ; Li, Jia1,2,3,5,6,7
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2025-05-08 |
| 页码 | 11 |
| 关键词 | Phosphatase of Regenerating Liver-3 (PRL3) tumor metastasis targeted therapies PRL-3-zumab |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/s41401-025-01563-1 |
| 英文摘要 | PRL-3, a protein tyrosine phosphatase (PTP), has a significant influence on the pathogenesis of various cancers with its overexpression significantly correlating with tumor invasion, metastasis and poor prognosis. It significantly affects tumor cell behavior through its involvement in cell proliferation, migration and metabolic processes. Furthermore, the interaction between PRL-3 and the tumor microenvironment characterized by its adaptability to stress and its role in metabolic reprogramming enhances tumor cell survival and dissemination. Targeted therapies against PRL-3, encompassing small molecule inhibitors and the monoclonal antibody PRL-3-zumab, have shown promise in clinical and preclinical studies, presenting new avenues for cancer treatment. In addition, innovative approaches such as CAAX motif-targeting agents and PRL-3 degradation strategies hold promise for developing more precise and effective interventions. This review explores PRL-3's multifaceted roles across different tumor types and microenvironments, while discussing current and emerging therapeutic strategies aimed at exploiting its oncogenic potential. |
| WOS关键词 | PROTEIN-TYROSINE PHOSPHATASES ; HUMAN GASTRIC-CANCER ; SIGNALING PATHWAY ; POOR-PROGNOSIS ; EXPRESSION ; INVASION ; PROMOTES ; MIGRATION ; PROGRESSION ; METASTASIS |
| 资助项目 | Shanghai Science and Technology Development Funds[24YF2755300] ; Guangdong High-level New RD Institute[2019B090904008] ; Guangdong High-level Innovative Research Institute[2021B0909050003] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001483874900001 |
| 出版者 | NATURE PUBL GROUP |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/317596]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Wang, Wen-long; Zhou, Yu-bo; Li, Jia |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Chem Biol, Shanghai 201203, Peoples R China 2.China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, Nanjing 210009, Peoples R China 3.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 4.Jiangnan Univ, Sch Pharmaceut Sci, Wuxi 214122, Peoples R China 5.Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China 6.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China 7.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China |
| 推荐引用方式 GB/T 7714 | Cao, Zi-tong,Mao, Jia-luo,Huang, Chang-ying,et al. PRL-3: unveiling a new horizon in cancer therapy[J]. ACTA PHARMACOLOGICA SINICA,2025:11. |
| APA | Cao, Zi-tong.,Mao, Jia-luo.,Huang, Chang-ying.,Wang, Han-lin.,Wang, Ming-zhi.,...&Li, Jia.(2025).PRL-3: unveiling a new horizon in cancer therapy.ACTA PHARMACOLOGICA SINICA,11. |
| MLA | Cao, Zi-tong,et al."PRL-3: unveiling a new horizon in cancer therapy".ACTA PHARMACOLOGICA SINICA (2025):11. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。